← back to search

Tibor Szarvas

Semmelweis University · HU
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Prostate Cancer Treatment and Research, and Urological Disorders and Treatments.
h-index
35
citations
3,629
works
260
NIH funding
primary concept
email

Recent publications

Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses
Cancer and Metastasis Reviews 2026cited by 0position: lastdoi
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms
The American Journal of Surgical Pathology 2025cited by 10position: middledoi
Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.
2025cited by 6position: contributordoi
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder
Advances in Anatomic Pathology 2025cited by 4position: middledoi
Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy.
2025cited by 4position: contributordoi
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
2025cited by 0position: contributordoi
Magnetic Resonance Imaging in Prostate Cancer Screening
JAMA Oncology 2024cited by 75position: middledoi
Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.
2024cited by 53position: contributordoi
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
2024cited by 10position: contributordoi
Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
2024cited by 8position: contributordoi
Near‐infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience
Journal of Surgical Oncology 2024cited by 5position: middledoi
Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience.
2024cited by 5position: contributordoi
Investigating the role of ultrasound-based shear wave elastography in kidney transplanted patients: correlation between non-invasive fibrosis detection, kidney dysfunction and biopsy results-a systematic review and meta-analysis.
2024cited by 5position: contributordoi
Safety and Efficacy of Vaginal Implants in Pelvic Organ Prolapse Surgery: A Meta-analysis of 161 536 Patients.
2024cited by 4position: contributordoi
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
2024cited by 1position: contributordoi
Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder<sup>†</sup>.
2024cited by 0position: contributordoi
[Rare tumors and tumor types of the urinary system in the 5th edition of the WHO classification 2022].
2024cited by 0position: contributordoi
Lifestyle-, environmental-, and additional health factors associated with an increased sperm DNA fragmentation: a systematic review and meta-analysis.
2023cited by 51position: contributordoi
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
2023cited by 28position: contributordoi
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
Molecular Cancer 2023cited by 21position: middledoi
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis.
2023cited by 17position: contributordoi
Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.
2023cited by 13position: contributordoi
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
2023cited by 13position: contributordoi
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
2023cited by 8position: contributordoi
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
2023cited by 6position: contributordoi
Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
2023cited by 6position: contributordoi
Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis.
2023cited by 6position: contributordoi
A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer.
2023cited by 1position: contributordoi
Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
2023cited by 0position: contributordoi
[Current diagnostic and treatment strategies for urachal cancer].
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Henning Reis · West German Heart and Vascular Center Essen44 papers (2019–2025)Boris Hadaschik · Deutsche Gesellschaft für Urologie38 papers (2019–2024) · 11 papers (2019–2024) · 7 papers (2019–2023)Ilona Kovalszky · HUN-REN Institute of Experimental Medicine3 papers (2020–2022)Csilla Oláh · Eötvös Loránd Tudományegyetem3 papers (2022–2022)Viktor Grünwald · Dana-Farber Cancer Institute3 papers (2022–2023)Veeru Kasivisvanathan · University of Turin2 papers (2024–2024)Christopher Darr · German Cancer Research Center2 papers (2021–2024)Christoph A. Klein · University Hospital Regensburg2 papers (2020–2020)Stephan Tschirdewahn · Kempten University of Applied Sciences2 papers (2021–2024)Jens T. Siveke · Heinrich Heine University Düsseldorf2 papers (2020–2023)Leubet Yirga · Deutschen Konsortium für Translationale Krebsforschung2 papers (2021–2024)Martin Metzenmacher · Deutsche Krebsgesellschaft eV2 papers (2020–2023)Renata Varaljai · Essen University Hospital2 papers (2020–2023)Alexander Schramm · Klinik und Poliklinik für Kinder- und Jugendmedizin2 papers (2020–2023) · 2 papers (2020–2021)Martin Schuler · Heinrich Heine University Düsseldorf2 papers (2020–2023)Smiths S. Lueong · University of Duisburg-Essen2 papers (2020–2023)Hans Neubauer · Deutschen Konsortium für Translationale Krebsforschung2 papers (2020–2023)